Pharsight

Belbuca generic

Belbuca is a pain management drug owned by Bdsi. It contains the active ingredient buprenorphine hydrochloride and comes in a film or buccal dosage forms. It was first authorized for market use on October 23, 2015. Belbuca holds a total of 3 drug patents, none of which have yet expired.

When will Belbuca generic be available?

Belbuca's last patent is set to expire on December 21, 2032. This suggests that the generic versions of Belbuca may be released as soon as this date passes. This release date is subject to change if any Para IV filings are made.

Belbuca uses

Belbuca is used for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The active ingredient buprenorphine hydrochloride is known for its effectiveness in treating pain by transmucosal delivery, providing targeted pain relief.

Belbuca patent expiration

Belbuca holds three main patents: US8147866 and US9655843, both titled 'Transmucosal delivery devices with enhanced uptake,' expiring on July 23, 2027; and US9901539, titled 'Transmucosal drug delivery devices for use in chronic pain relief,' expiring on December 21, 2032. This is when the generic versions of Belbuca are expected to become available. Below are the details of the patents:

Belbuca dosage

Want to ask something?